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Insulin-like growth factor II acts
through an endogenous growth pathway
regulated by imprinting
m early mouse embryos
Daniel A. Rappolee, l Karin S. Sturm, 2 0 l e Behrendtsen, Gilbert A. Schultz, 3 Roger A. Pedersen,
and Zena Werb 4
Laboratory of Radiobiology and Environmental Health, Department of Anatomy, and Program in Developmental Biology,
University of California, San Francisco, California 94143-0750 USA

We present evidence that insulin-like growth factor II (IGF-II) mediates growth in early mouse embryos and
forms a pathway in which imprinted genes influence development during preimplantation stages, mRNA and
protein for IGF-II were expressed in preimplantation mouse embryos, but the related factors IGF-I and insulin
were not. IGF-I and insulin receptors and the IGF-II/mannose-6-phosphate receptor were expressed.
Exogenous IGF-II or IGF-I increased the cell number in cultured blastocysts, but a mutant form of IGF-II that
strongly binds only the IGF-II receptor did not. Reduction of IGF-II expression by antisense IGF-II
oligonucleotides decreased the rate of progression to the blastocyst stage and decreased the cell number in
blastocysts. Preimplantation parthenogenetic mouse embryos expressed mRNA for the IGF-II receptor but not
for either IGF-II ligand or the IGF-I receptor, indicating that the latter genes are not expressed when inherited
maternally. These data imply that some growth factors and receptors, regulated by genomic imprinting, may
control cell proliferation from the earliest stages of embryonic development.

[Key Words: Insulin-like growth factor; PCR; antisense oligonucleotides; insulin receptor; blastocysts; zygotic
transcription; receptor tyrosine kinase; genomic imprinting]
Received August 2, 1991; revised version accepted April 9, 1992.

The mammalian embryo can behave as a free-living entity from fertilization to implantation and is capable of
growing in culture in the absence of any exogenous
growth factors (Biggers et al. 1988). However, the rate of
growth of cleavage-stage mouse embryos in culture is
density-dependent, suggesting that diffusible growth factors of embryonic origin may regulate this growth (Paria
and Dey 1990). Early cleavage-stage mouse embryos can
be combined or halved without effect on the size of neonates, demonstrating their extensive capacity for regulation (Kelly 1977; for review, see Pedersen 1986) and
implying a process of embryonic growth regulation
(Buehr and McLaren 1974; Lewis and Rossant 1982).
During preimplantation stages the mouse embryo undergoes cleavage and differentiates into a blastocyst that
possesses the precursors for the embryo proper (the inner
cell mass) and the placenta (the trophectoderm). ComPresent addresses: ~Departments of Obstetrics and Gynecology, and Cell,
Molecular and Structural Biology, Northwestern University, Chicago,
Illinois 60611 USA; 2Children's Medical Research Foundation, Royal
Alexandra Hospital for Children, Camperdown, New South Wales 2050,
Australia; SDepartment of Medical Biochemistry, University of Calgary,
Calgary, Alberta, Canada T2N 4N1.
4Corresponding author.

paction, the epithelialization of the embryo at the eightcell stage, is required for the determination of these precursors (for review, see Cruz and Pedersen 1991) and is
dependent on the transcription of the zygotic genome
after its activation at the two-cell stage (Flach et al. 1982;
Pik6 and Clegg 1982). We have shown previously that
cleavage-stage mouse embryos transcribe and translate
mRNA for transforming growth factor (TGF)-a, TGF-[31,
and platelet-derived growth factor-A chain, but not for
nerve growth factor, basic fibroblast growth factor, epidermal growth factor, or granulocyte colony-stimulating
factor (Rappolee et al. 1988a; for review, see Rappolee et
al. 1990). Interleukin-6 and leukemia inhibitory factor/
differentiation-inhibiting activity are also expressed at
the blastocyst stage (Conquet and Brulet 1990; Murray et
al. 1990). However, no complete circuit of endogenous
growth factor ligand and receptor has been elucidated in
preimplantation mammalian embryos.
Insulin and its relatives constitute a family of growth
factors that might be implicated in growth regulation of
early embryos. Early mouse embryos bind insulin, which
affects their rate of protein synthesis in culture (Harvey
and Kaye 1988; Mattson et al. 1988). The insulin family
includes insulin-like growth factor (IGF)-I, IGF-II, and
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insulin (two nonallelic genes)(Sara and Hall 1990). These
factors are related by sequence and have insulin-like
metabolic effects. In adult animals, insulin expression is
regulated by glucose, and IGF-I expression is regulated by
growth hormone, but the regulation of IGF-II is not well
understood (Sara and Hall 1990).
There are three known insulin-like growth factor receptors. The IGF-II/mannose-6-phosphate receptor (also
called the type-2 receptor, but referred to in this report as
the IGF-II receptor) binds IGF-II strongly, binds IGF-I
weakly, but does not bind insulin at all (Roth 1988;
Czech 1989). It also binds glycoproteins containing mannose-6-phosphate moieties, but these proteins do not activate the G protein-mediated signaling induced by the
binding of IGF-II (Okamoto et al. 1990a, b). The IGF-I
receptor (also called the type-1 receptor or IGF-I/IGF-II
receptor) and insulin receptors are related tyrosine kinases activated by ligand binding. The IGF-I receptor is
activated equally by IGF-II and IGF-I, but the insulin
receptor is activated more strongly by insulin than by
IGF-I (Roth 1988; Sakano et al. 1991). Purified insulin
receptor isolated from placenta binds IGF-II nearly as
well as insulin, but the mitogenic capacity of IGF-II for
the insulin receptor is not known (Sakano et al. 1991).
Mitogenic responses to IGF-II are mediated by the IGF-I
receptor not by the IGF-II receptor (Kiess et al. 1987;
Osborne et al. 1989; for review, see Czech 1989).
Postimplantation rodent embryos possess the IGF-II
receptor (Smith et al. 1987; Senior et al. 1990) and the
IGF-I receptor in greater quantities than the insulin receptor ISmith et al. 1987), but the relative roles of the
IGFs and their receptors in early development are still
unclear. IGF-II has been implicated in postimplantation
mouse growth (DeChiara et al. 1990, 1991), but IGF-II
transcripts have not been detected in mouse (Lee et al.
1990) or human (Brice et al. 1989; Ohlsson et al. 1989b)
preimplantation embryos. IGF-II expression has been associated most closely with mesoderm (Heath and Shi
1986; Stylianopoulou et al. 1986, 1988; Beck et al. 1987;
Han et al. 1987b), which arises at gastrulation.
Regulation of growth in early mammalian embryos
might be modulated by genomic imprinting, the selective differential expression of genes initiated by a process
of unknown mechanism during gametogenesis. IGF-II
ligand is imprinted when inherited maternally, and IGFII receptor is imprinted when inherited paternally (DeChiara et al. 1990; Barlow et al. 1991).
In this study, we analyzed preimplantation zygotic
mouse embryos for the expression and function of three
ligands and receptors in the IGF family and examined
parthenogenetic embryos for evidence of genomic imprinting at preimplantation stages.

Results
Preimplantation zygotic mouse embryos express IGF-II
We used the sensitive reverse transcription-polymerase
chain reaction (RT-PCR) technique, which can detect as
few as 10-100 mRNA transcripts in a single cell IRap-
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polee et al. 1988a, b, 1989), to determine whether embryos express transcripts for the insulin family members.
IGF-II transcripts were detected first at the two-cell stage
in samples of 10 embryos containing a total of 3 ng of
RNA (Pik6 and Clegg 1982) and then increasingly
through the blastocyst stage in samples containing up to
15 ng of total RNA (Fig. la, b). Insulin and IGF-I transcripts were not found before implantation (Fig. l c, e). In
contrast, an IGF-I signal was detected in 20 pg of macrophage mRNA (Fig. ld), and an insulin signal was detected in 20 pg of pancreas mRNA (Fig. lf). RT-PCR
products were validated by restriction enzyme mapping,
sequence analysis, and Southern blot analysis (data not
shown). IGF-II transcripts were expressed at the late twocell stage when the zygotic genome is first transcribed
and after much of the maternal contribution of transcripts has been degraded (Pik6 and Clegg 1982; Schultz
1986).
The IGF-II gene gives rise to two mRNAs; the one
expressed more ubiquitously does not code for a protein
in reticulocyte lysate systems (Frunzio et al. 1986; Graham et al. 1986). Because the presence of growth factor
mRNA cannot be equated with translation of the RNA
to protein (Dinarello 1989), we analyzed blastocysts for
the presence of IGF-II polypeptide immunologically.
There was insufficient protein to detect metabolically
labeled growth factors from mouse blastocysts by immunoprecipitation or immunoblotting {data not shown).
However, polypeptides reacting with a polyclonal antibody to rat IGF-II were seen in all cells of the blastocyst
by immunocytochemistry {Fig. 2). All staining was attenuated by preabsorbing the antibody with purified rat
IGF-II. Nevertheless, these data do not necessarily indicate that all cells within the blastocyst are sites of IGF-II
synthesis. It is possible that some cells produce IGF-II
and that others take it up by endocytosis, because all
cells of the blastocyst apparently produce IGF-II receptor, as judged by immunocytochemistry with anti-receptor antibodies (data not shown). We conclude that preimplantation mouse embryos begin to transcribe IGF-II
soon after activation of zygotic transcription at the twocell stage and accumulate immunoreactive polypeptide
at the blastocyst stage (Schultz 1986).
Preimplantation mouse embryos express receptors
for IGF-H
Unfertilized eggs and zygotic embryos at the two-cell,
four-cell, eight-cell, and blastocyst stages were assayed
by RT-PCR for insulin receptors, IGF-I receptors, and
IGF-II receptors. Transcripts for the IGF-II receptor were
detected at the two-cell stage (Fig. 3a). IGF-I and insulin
receptors were not expressed until after compaction, at
the eight-cell stage {although in one of five experiments
there was a weak signal for IGF-I receptor at the two-cell
stage) (Fig. 3c, e); all receptors were detected in ~<2 ng of
control RNA {Fig. 3b, d, fJ. Taken together, these observations suggested that among the insulin family of growth
factors, only IGF-II could potentially function as an endogenous ligand in preimplantation mouse embryos and
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Figure 1. Expression pattern of mRNA transcripts for IGFs in preimplantation mouse embryos. Preimplantation mouse embryos were
obtained in groups of 100-200 from superovulated females 24 hr after injection of human chorionic gonadotropin [(UE) unfertilized
one-cell, 36 hr p.c.; (2) two-cell, 60 hr p.c.; (8) eight-cell, 96 hr p.c.; (B) blastocyst, and (8.5 day) at 8.5 d.g.]. Whole-cell RNA was purified

and reverse transcribed, and cDNA from -10 embryos (-3.5 ng/10 unfertilized eggs, 2.4 ng/10 two-cell, 6.9 ng/10 eight-cell, 14.2
ng/10 blastocysts; Pik6 and Clegg 1982) was amplified for 60 cycles of PCR and electrophoresed in agarose. Positive controls were 200
ng of whole-cell RNA from nullipotent embryonal carcinoma stem cells (Nulli) or 8.5-d.g. embryos. (a) IGF-II transcripts (266 bp); (b)
10-fold dilution series of mRNA from differentiated F9 cells; (c) IGF-I transcripts (210 bp); (d) dilution series of mRNA from endotoxinstimulated macrophages; (e) insulin transcripts (299 bp); {f) dilution series of mRNA from pancreas. Arrows indicate the location of the
PCR product. Data are shown as negative images of ethidium bromide-stained gels. In b, d, and f, amounts ranging from 20 pg through
2000 ng of whole RNA was reverse transcribed and 2 pg through 200 ng (one-tenth of reverse transcription) was analyzed by PCR.

that it could act through the IGF-I receptor, the IGF-II
receptor, or the insulin receptor.

Receptors for IGF-II function in preimplantation
mouse embryos
It has been shown previously that insulin binds and
stimulates mouse embryos soon after compaction
(Harvey and Kaye 1988; Mattson et al. 1988) and that
inner cell mass cells from mouse blastocyst outgrowths
bind IGF-I, IGF-II, and insulin (Mattson et al. 1988). This
indicates that one or more members of the insulin family
of receptors must be functional during preimplantation
mouse embryo development. We first determined the effect of adding recombinant human IGF-II to mouse embryos during culture from two-cell stage to blastocyst.
Examination of sequential photographs of embryos cultured with IGF-II or insulin revealed no obvious morphological effects or modulation of the rate of progression
through the cleavage stages to compaction; however, the

time of cavitation was accelerated (data not shown). During the last 4 hr of culture, [3SS]methionine was added
and the blastocysts were assayed for incorporation of radiolabeled methionine into protein by precipitation with
trichloroacetic acid (TCA). IGF-II increased methionine
incorporation significantly (P < 0.05, Student's t-test) by
1.8- and 3.5-fold in two experiments (Fig. 4); IGF-I stimulated methionine incorporation to a lesser extent. In
agreement with the results of Harvey and Kaye (1988),
we also found that insulin increased the specific activity
of radiolabeled proteins significantly (P < 0.05, Student's
t-test) by 2- to 2.5-fold in two experiments (Fig. 4). However, the patterns of [3SS]methionine-labeled proteins
from untreated and IGF-II-treated embryos were qualitatively indistinguishable by one-dimensional SDS-polyacrylamide gel electrophoresis (data not shown). These
observations show that IGF-II has a significant effect on
preimplantation embryonic growth.
At the growth factor concentrations used in these first
tests of function for embryonic receptors, it was not pos-
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Figure 2. Expression of IGF-II polypeptide in mouse blastocysts. Cultured mouse
blastocysts were centrifuged onto coverslips and prepared for indirect immunofluorescence by using polyclonal antibody to
rat IGF-IIbefore (a,b) and after {c,d) absorption of the antibody with a 1000-fold excess of rat IGF-II. (a,c) Phase micrographs;
(b,d) fluorescence micrographs.

sible to determine whether the IGF-II receptor the IGF-I
receptor, or the insulin receptor was mediating the effects of IGF-II on protein accumulation. Because no
changes were seen in the rate of progress through early
cleavage or compaction after IGF-II exposure, the IGF-II
receptor is either not functional in the early cleavage
stages or is not sufficient to regulate events in early development. We compared the effects of IGF-II, IGF-I, and
[Leu27]IGF-II, a mutant form of IGF-II that binds strongly
to the IGF-II receptor (Beukers et al. 1991), on the growth
of preimplantation mouse embryos. Mouse embryos cultured from the two-cell to the blastocyst stage had increased numbers of cells after exposure to IGF-I or IGF-II
but not after exposure to [Leu27]IGF-II (Fig. 5). Cell number increased significantly (1.2- to 1.4-fold in two experiments; P < 0.05, Student's t-test) at concentrations of
IGF-I and IGP-II that were near the K d o f the IGF-I receptor (Roth 1988; Czech 1989), but 10-fold higher concentrations of [Leu~7]IGF-II had no effect. Because these
growth factors appeared to act only after compaction,
these increases in cell number occurred in one to two
cell divisions in the presence of a number of other endogenous growth factors (Rappolee et al. 1990) and thus
are highly significant. These data suggest that IGF-II induces growth in preimplantation mouse embryos
through the IGF-I receptor or the insulin receptor and
not through the IGF-II receptor, which binds only to IGFII or [Leu27]IGF-II.

Reduction in IGF-II expression by antisense
oligonucleotides slows embryonic growth
We then analyzed whether the endogenous embryonic
IGF-II functions in embryonic growth. Antisense oligo-
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nucleotides have been used to reduce the expression and
function of intracellularly expressed genes such as c-myc
(Holt et al. 1988) and growth factors (Becker et al. 1989),
and thus they provide a proven method for decreasing
gene expression in preimplantation mouse embryos
(Bevilacqua et al. 1988). We used sequence-specific oligonucleotides for IGF-II that were complementary for
the coding region of the first 6 amino acids (MarcusSekura 1988; Stein and Cohen 1988). The preimplantation embryos tolerated the oligonucleotides well, and
toxicity with control sense or random oligonucleotides
was seen only above 100--200 I~M; with control oligonucleotides below 100 ~M, the embryos grew at least as
well as untreated embryos. However, a concentrationdependent effect of antisense oligonucleotides was seen
between 1 and 100 ~M, with a peak of sensitivity at 30
~M. At this concentration, -106 molecules of the sense
or antisense IGF-II oligonucleotides were present at
steady state in the blastocyst, as detected by autoradiography and liquid scintillation spectrometry (data not
shown).
Culture of mouse embryos from the two-cell to the
blastocyst stage with antisense IGF-II oligonucleotides
in two separate experiments resulted in the loss of immunochemically demonstrable IGF-II antigen compared
with embryos incubated with sense oligonucleotides,
with an estimated average decrease in immunofluorescence of at least 75% (Fig. 6a-d). In contrast, the average
amount of actin seen with rhodamine-phalloidin in two
experiments was the same in embryos treated with either sense or antisense oligonucleotides (Fig. 6e, f). With
normal rabbit serum, no antigens were detected (Fig.
6g, h). The amount of IGI:-II mRNA demonstrable by
quantitative RT-PCR analysis was reduced by antisense
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was unaffected {Fig. 7a). The effects of antisense IGF-II
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proportion of embryos reaching the blastocyst stage after
48 and 72 hr also decreased significantly (P < 0.05, Student's t-test) with the second antisense oligonucleotide
but was not affected by the second sense oligonucleotide.
Preimplantation mouse embryos cultured with antisense oligonucleotides from the two-cell to the blastocyst stage grew significantly more slowly (P < 0.05, Stu-

500

~_~

20(

~ u
:S

10(

65
In
o
Medium
Alone
Experiment

IGF-I

1

IGF-II

Insulin

Medium
Alone

0

Figure 3. Expression pattern of mRNA
transcripts for IGF receptors in preimplantation mouse embryos. Transcripts for
IGF-II receptor (186 bp) (a,b), IGF-I receptor (345 bp)(c,d), and insulin receptor (319
bp) {eft} were assayed as described in the
legend to Fig. 1. Dilution series for positive controls were obtained from differentiated F9 cells (b,d) and endotoxin-stimulated macrophages {f). As in Fig. 1, whole
RNA from 10 embryos at each stage was
examined; abbreviations are also the
same. Data are shown as negative images
of ethidium bromide-stained gels.
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Figure 4. Stimulation of protein synthesis
by IGF-II in preimplantation mouse embryos.
Mouse embryos were cultured from the twocell stage for 48 hr to the blastocyst stage with
100 nM IGF-II, IGF-I, or insulin. During the
last 4 hr of culture, blastocysts were incubated with 1 m C i / m l of [3SS]methionine
(3000 Ci/mmole). Incorporation into proteins
was measured by liquid scintillation spectrometry after acid precipitation. Protein synthesis was enhanced significantly after insulin, IGF-II, and IGF-I, compared with medium
alone (Student's t-test; P < 0.05). Three independent experiments were performed, with
60 blastocysts in each experiment. Results of
two experiments are shown. The incorporation of [3SS]methionine into untreated embryos was 826 and 1250 cpm in the two experiments. The Bachem preparation of IGF-I
was used in these experiments. Bars,
mean -+ S.D.

GENES & DEVELOPMENT

943

Downloaded from www.genesdev.org on May 5, 2007
Rappolee et al.

>, 4
•~

3

"~

2

--

1

8

c
0.05

5.0
0.5

0.05
50.0

5.0
0.5

0.05
50.0

Medium

IGF-I

IGF-II

Alone

(ng/20pl)

(ng/20~ul)

5.0
0.5

50.0

Leu-IGF-II
(ng/20pl)

Figure 5. Demonstration that IGF-I[ stimulates cell growth in
preimplantation mouse embryos through the IGF-I receptor.
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ng/20 ~1 of IGF-I, IGF-II, or [Leu27]IGF-II, fixed onto coverslips
with ethanol-acetic acid, and stained with Hoechst 33258, and
nuclei were counted. Twenty embryos were counted from each
group. The two highest concentrations of IGF-I and the three
highest concentrations of IGF-II had significantly higher effects
on growth than did medium controls {Student's t-test;
P < 0.05). The Amgen preparation of IGF-I was used in these
experiments. The decrease in cell number at the highest dilutions was probably the result of accumulation of plasticizer contaminants during the serial dilution of the proteins and masked
the effects at low concentrations but still permitted observation
at higher concentrations. The decreased cell number at the
highest dilution was the result of accumulation of contaminants during serial dilutions.

DeChiara et al. (1990) that the maternally inherited IGFII gene is imprinted in later development. However, actin gene transcripts were detected throughout preimplantation development in both zygotic embryos and
parthenogenotes (Fig. 8b).
Peri-implantation parthenogenotes did not express the
IGF-I receptor gene or expressed it only weakly (Fig. 8c).
These data indicate that the IGF-I receptor, or a gene
regulating it, may also be imprinted when inherited maternally.
The number of cells in parthenogenetic blastocysts
treated with 50 nM IGF-II (95 -+ 10.8% control, for two
experiments) for 48 hr was not significantly different
from that in untreated parthenogenotes (P ~< 0.846; Student's t-test); the number of cells in zygotic blastocysts
treated with IGF-II was 135 -+ 8.6% control (P ~< 0.005).
This is in agreement with the hypothesis that IGF-II may
act as a mitogen by the IGF-I receptor, but further experiments on the mitogenic effects of IGF-II through the
insulin receptor and the imprinting status of the insulin
receptor are required.
Transcripts for the IGF-II receptor were expressed
equally in zygotes and parthenogenotes (Fig. 8d), in keeping with previous observations that this gene is imprinted when inherited paternally (Barlow et al. 1991).
These data suggest that the endogenous growth factor

IGF'I I
dent's t-test) {Fig. 7b) and had an average of 20% fewer
cells than those cultured with sense oligonucleotides
(Fig. 7c).
Cytotoxicity did not account for the decreased cell
number and slowing of cavitation, because when the ant{sense oligonucleotide-treated embryos were cultured
an additional 24 hr beyond the 48- to 72-hr time point,
the fraction reaching late blastocyst stage was indistinguishable from that of sense oligonucleotide-treated embryos. Moreover, exogenous IGF-II reversed the deficiency in embryo growth that resulted from the reduction in endogenous IGF-II; the number of cells in mouse
embryos cultured with ant{sense IGF-II oligonucleotides
in the presence of recombinant IGF-II was significantly
greater than that in embryos cultured with ant{sense
IGF-II oligonucleotides alone (Fig. 7c).

AS

AS

Actin

AS
Control

Imprinting disrupts the IGF-II growth circuit
in parthenogenetic mouse embryos
Imprinting of the IGF-II gene has been observed previously by DeChiara et al. (1990). To determine whether
imprinting is detectable in preimplantation embryos, we
exploited the process of parthenogenesis to obtain embryos that have a diploid genome of only maternal origin; this is produced by suppression of cytokinesis in
activated oocytes. In contrast to zygotic embryos (Fig. 1),
no IGF-II transcripts were apparent in preimplantation
parthenogenotes (Fig. 8a), extending the observation by
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AS
Figure 6. Effect of antisense IGF-II oligonucleotides on endogenous IGF-II antigen in preimplantation mouse embryos. Preimplantation mouse embryos cultured from the two-cell stage
with sense (S} (a,b,e,g) or ant{sense (AS)(c,d,f,h} oligonucleotides were fixed and subjected to indirect immunofluorescence
with polyclonal anti-rat IGF-II (a,b,c,d) or nonimmune rabbit
serum (NRSJ (g,h) or stained with rhodamine-phalloidin to detect actin (e,f).
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C

circuit in early embryos that is dependent on IGF-II is
disrupted by imprinting in parthenogenetic embryos.

Discussion
We have found that IGF-II transcript and polypeptide and
transcripts for its receptors are expressed and form an
endogenous circuit that is functional during normal preimplantation mouse embryogenesis. It is probable that
endogenous IGF-II mediates growth through the IGF-I
receptor or the insulin receptor rather than the IGF-II
receptor, because IGF-II and IGF-I, but not [Leu27]IGF-II,
increased cell number in preimplantation mouse embryos in a concentration range suggesting activation of
IGF-I receptor or insulin receptor. Although both IGF-II
ligand and receptors for IGF-II are expressed before compaction, reduction of endogenous IGF-II or addition of
exogenous IGF-II had no apparent effect on morphology
at the earliest stages, as judged by cell divisions measured during precompaction cleavage or by the timing of
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compaction. All effects resulting from perturbing this
pathway were on growth and metabolism measured after
the morula stage. Incorporation of radiolabeled methionine and growth rate were affected significantly by treatments that increased or decreased the effects of IGF-II in
cultured preimplantation embryos. Recent IGF-II genetargeting experiments by DeChiara and co-workers
{19901 demonstrated a 40% reduction in birth weight of
IGY-II-mutant neonates, similar to the reduction in
growth {measured by reduction in cells per blastocyst)
that we observed in preimplantation embryos in the
presence of antisense IGF-II oligonucleotides, but these
workers did not study whether there was a decrease in
the rate of early embryonic development of embryos that
were heterozygous or homozygous for the mutation (DeChiara et al. 1991).
As we found that transcripts for IGF-I and insulin
ligands are not expressed in cleavage-stage embryos, yet
their receptors function {Harvey and Kaye 1989, 1991~
Gardner and Kaye 1991), we speculate that matemal
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8. IGF-II and IGF receptor expression in parthenogenetic embryos. Parthenogenetic embryos were generated by ethanol activation, followed by suppression of
second polar body emission by cytochalasin D, and cultured to various stages before processing and assay of mRNA transcripts by RT-PCR. Normal zygotic embryos were generated and assayed for
mRNA transcripts as described in Figs. 1
and 3. The expression of mRNA transcripts for {a) IGF-II, (b) actin, (c) IGF-I receptor, and (d) IGF-II receptor in unfertilized egg (UE), eight-cell (8), blastocyst
stage-embryos (B), and 3- and 7-day blastocyst outgrowths (OG) is shown in zygotic
(left) and parthenogenetic (right} embryos.
eDNA reverse-transcribed from RNA from
about five embryos was used for the PCR
analysis in each lane. Data are shown as
negative images of ethidium bromidestained gels.
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IGF-I and insulin form a maternal-embryonic pathway
that also modulates cell growth of preimplantation
mouse embryos. IGF-I is found in the uterine fluid of
some mammals (Ko et al. 1991). This idea is supported
by recent evidence that insulin increases cell number in
the inner cell mass and that there are fewer cells in the
inner cell mass of blastocysts from diabetic animals (Liu
et al. 1989; Harvey and Kaye 1990; Pampfer et al. 1990),
although direct evidence for in vivo effects is lacking.
We showed previously that TGF-ot is transcribed and
translated in cleavage-stage mouse embryos (Rappolee et
al. 1988a), and we have also observed that antisense oligonucleotides specific for TGF-~ slow the growth of preimplantation mouse embryos, whereas exogenous
TGF-ot increases their protein synthetic rate (D.A. Rappolee and Z. Werb, unpubl.). TGF-c~ did not regulate morphogenetic events such as compaction but, rather, altered the growth rate, as reported recently for growth
factors acting through the epidermal growth factor receptor (Paria and Dey 1990). These results suggest that
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endogenous growth factors such as IGF-II and TGF-oL do
not regulate differentiation events in preimplantation
mouse embryos but regulate metabolic processes that
may modulate cell proliferation rates. Limited increases
in protein synthesis caused by addition of several growth
factors (IGF-II, insulin, or TGF-cx) and limited decreases
in cell growth rate caused by attenuating the expression
of IGF-II or TGF-~ alone suggest that growth is regulated
in preimplantation embryos through multiple, partially
redundant, growth factor circuits. Further experiments
are required to define this redundancy in vitro and in vivo.
The use of a sensitive method such as RT-PCR raises
a question about the biological relevance of low transcript levels. Previous reports have shown that IGF-II
mRNA is not expressed in mouse or human blastocysts
assayed by in situ hybridization (Beck et al. 1987; Ohlsson et al. 1989b~ Lee et al. 1990}. We have found that
IGF-II is expressed in mouse embryos when assayed by
the RT-PCR technique, that the polypeptide is expressed as assayed by immunofluorescence, and that
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IGF-II expression has biological function. We have found
previously that TGF-oL mRNA is expressed in mouse embryos at 7.5 days of gestation (d.g.) {Rappolee et al. 1988a)
when equivalent-stage rat embryos were found to be negative by in situ hybridization (Han et al. 1987a). It therefore seems likely that RT-PCR can detect biologically
significant levels of growth factor mRNA not detected
by in situ hybridization. This should not be surprising,
because a growth factor receptor with a Ka of 10-13 is
activated by a polypeptide concentration of about one
molecule per fibroblast cell volume (assuming that a fibroblast has a volume of -104 p.m3) and growth factors
normally act within a few cell diameters of their source
(Deuel 1987). Other genes such as c-myc reach maximum levels of five transcripts per cell during a response
to optimal levels of platelet-derived growth factor (Deuel
1987). Transcripts of developmentally important genes
such as the limb deformity gene in the apical ectodermal
ridge in mouse embryos (Zeller et al. 1989) are also not
detected by in situ hybridization. Therefore, even very
small numbers of mRNA transcripts might be biologically significant if they are involved in gene regulation or
participate in signaling cascades.
When exogenous IGF-II ligand was added simultaneously with IGF-II antisense oligonucleotides, the effects caused by reduction of the endogenous IGF-II were
reversed. Thus, the temporal or spatial distribution of
endogenous IGF-II can be mimicked, in part, by exogenous IGF-II. It is likely that antisense IGF-II, which attenuates the expression of the endogenous IGF-II, slows
embryonic growth through a specific mechanism. The
coding sequence of the first 6 amino acid residues of
IGF-II is not homologous with that of any other genes
expressed in the preimplantation embryo, and two different antisense IGF-II oligonucleotides produced similar
effects, confirming that these effects are specific.
Because IGF-II clearly did not account for all the cell
proliferation in the early embryo, it is likely that other
growth factors are involved. To assess whether various
combinations of growth factors mediate any absolute effects on differentiation or growth, we must determine
how they interact. Because at least 12 growth factor
mRNAs are expressed during preimplantation mouse
embryogenesis (Rappolee et al. 1988a, 1990; Murray et
al. 1990; unpubl.), this is not a simple task. New approaches to eliminating growth factors selectively must
be perfected to resolve their roles. Although antisense
oligonucleotides cause cytotoxicity in embryos at relatively low concentrations (100-200 ~M), several could be
used at the 30 ~M optimal concentrations observed in
this study to attenuate expression of multiple growth
factors simultaneously. Alternatively, growth factors
can be added in combination or heterologous growth factors can be added with antisense IGF-II to test for redundancy of action; or growth factors can be deleted by homologous recombination (DeChiara et al. 1990), after
which multiply homozygous mutants could be generated to investigate the roles of growth factors that act
through redundant circuits.
That control of growth in early pre- and postimplan-

tation mammalian embryos is regulated by genomic imprinting might be important from both developmental
and evolutionary perspectives. Developmentally, expansion of different lineages of cells must be timed properly
and maintained in proportion both intraembryonically
and between the embryonic and maternal tissues. That
imprinting is manifested from the two-cell stage, when
zygotic transcription first occurs, suggests that the
mechanisms for transcriptional regulation of these
genes, at the level of either chromatin or DNA modification, are already stereotyped and in place when the
genome is activated, much earlier than the mechanisms
involved in X-chromosome inactivation (Lock et al.
1987; for review, see Grant and Chapman 1988). Evolutionarily, it has been suggested that imprinting might
occur because of conflicting parental interests in the
growth rates of offspring in plants and viviparous organisms; male gene transmission is favored by fast embryonic growth in competition with other males, whereas
female gene transmission is favored by maximizing F 1
generation group size in competition with other females
(Haig and Westoby 1989). In plants, the growth of the
endosperm, the organ that acquires nutrients for the zygote, is under paternal control and is maternally imprinted {for review, see Haig and Westoby 1989). In mammals, the growth of the placenta, the organ that acquires
nutrients for the zygote or the embryo proper, would be
predicted to be under paternal control. Positively acting
elements in early embryonic growth circuits would be
predicted to be paternally transcribed, and negatively
acting elements would be predicted to be maternally
transcribed. It is interesting to note that IGF-II ligand
and receptor and IGF-I receptor are highly expressed in
trophectoderm, the precursor to placenta, soon after implantation of rodent embryos, and that IGF-II functions
in a paracrine manner in human placentation (Rotwein
et al. 1987; Stylianopoulou et al. 1988; Ohlsson et al.
1989a, b; Senior et al. 1990).
The hypothesis of Haig and Graham (1991) predicts
that imprinting of growth factors such as IGF-II, IGF-II
receptor, and IGF-I receptor might regulate embryonic
growth in mammals in utero. Our results showing imprinting of the IGF-I receptor and IGF-II ligand when
inherited maternally are consistent with this hypothesis,
but we cannot rule out the possibility that genomic imprinting of other growth factors and receptors may function in maintaining balance in the proportion and timing
of expansion of cell lineages in the embryo. Further studies on the expression, function, and imprinting status of
other elements in IGF growth circuitry (e.g., IGF-binding
proteins}, and of other growth factor circuits, may delineate these hypotheses. The analysis of genes expressed in
uniparental parthenogenetic and androgenetic embryos
may serve as a rapid, general method for identifying genomically imprinted genes (Pedersen et al. 1992).
It is notable that the IGF-II/mannose-6-phosphate receptors in chicken and Xenopus do not bind IGF-II (Clairmont and Czech 1989) and thus may function only in the
transport of proteins targeted for lysosomes, whereas
mammalian IGF-II/mannose-6-phosphate receptors bind
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IGF-II as well as mannose-6-phosphate-rich proteins
(MacDonald et al. 1988) through different extracellular
domains. It has been hypothesized that the IGF-II receptor in m a m m a l s suppresses growth by removing extracellular IGF-II (Haig and G r a h a m 1991). Because of these
evolutionary considerations, it will be interesting to
evaluate the structure of the IGF-II receptor and its function in early embryogenesis in greater detail. There is
evidence that IGF-II can stimulate growth in cells only
after stimulation by other growth factors (Nishimoto
and Kojima 1989), and that this effect m a y depend on
Ca 2 + influx, w h i c h depends on IGF-II binding to a Gi2binding IGF-II/mannose-6-phosphate receptor (Nishimoto and Kojima 1989; O k a m o t o et al. 1990a, b). However,
the Ca 2 +-dependent mitogenic signal m a y also be mediated by IGF-II stimulation of the IGF-I receptor (Nishimoto and Kojima 1989). Our data strongly suggest that
the IGF-II receptor is not the transducer of the mitogenic
signal of endogenous IGF-II. The mitogenic signal of IGFII might be transduced by the IGF-I receptor or insulin
receptor. The insulin receptor (Sakano et al. 1991) and
IGF-I receptor (Roth 1988) can bind IGF-II nearly as well
as their cognate ligands. It is not clear from our data
whether the mitogenic activity of IGF-II in embryos is
transduced by the IGF-I or insulin receptors, but attenuation of the expression of these receptors m a y distinguish between these possibilities.
Our data are the first to show directly that an endogenous growth factor plays a role in cell proliferation during the earliest stages of mouse development. Our results c o m p l e m e n t the analysis of long-term effects of
IGF-II ligand on later embryonic and fetal growth in animals containing a m u t a n t IGF-II gene (DeChiara et al.
1990). However, our understanding of the role of IGF-II
in preimplantation mouse embryogenesis will require
further studies. It is possible that growth rates during
peri-implantation development are decisive in the establishment and proliferation of the extraembryonic lineages and, thereby, in the subsequent growth rate of the
fetus. Still to be evaluated are synergism with other
growth factors, signal transduction and gene induction
by embryonic IGF-II, and location and function of the
IGF-binding proteins in peri-implantation mouse embryos.

Materials and methods

separately from Bachem. Polyclonal rabbit anti-rat IGF-II antibody and rat IGF-II/multiplication stimulation activity (MSA)
were gifts of P. Nissley (National Institutes of Health).
[Leu27]IGF-IIand recombinant IGF-I (Amgen) were the gifts of R.
Rosenfeld (Stanford University). The IGF-I from Bachem was of
lower specific activity than that from Amgen.

Mouse eggs and embryos
Standard techniques were used for obtaining eggs and zygotes
(Hogan et al. 1986). Female CD-1 or CF-1 mice (6-10 weeks old,
Charles River) were injected with 10 IU of pregnant mares' serum gonadotropin (Equitech), followed by an injection 44-48 hr
later of 5 IU of human chorionic gonadotropin (hCG, Serono).
After the second injection, females were housed overnight with
C57BL/6J x SJL/J F1 hybrid males {Jackson Laboratories). Embryos were obtained at the following stages: one-cell [12 hr postco(turn (p.c.)], two-cell (36 hr p.c.), four-cell {48 hr p.c.), eightcell (60 hr p.c.), and blastocyst (84-96 hr p.c.). Unfertilized eggs
were flushed from the oviducts of superovulated females, and
later embryos were dissected from the uteri of females (7.5 or
8.5 d.g.). Embryos were flushed from the uteri or oviducts of
mice with flushing medium-I (FM-I) (Spindle 1980) containing 3
mg/ml of bovine serum albumin. The embryos were then
washed through 6 drops of FM-I. Mature oocytes/unfertilized
eggs were flushed from oviducts 18 hr after hCG injection and
then treated with hyaluronidase to remove adherent cumulus
cells (Hogan et al. 1986). All eggs and embryos were sorted and
freed of debris under a dissecting microscope.

Parthenogenetic embryos
Parthenogenetic activation of mouse oocytes was performed essentially as described by Barton et al. (1987), with minor modifications (K.S. Sturm, M.L. Flannery, and R.A. Pedersen, unpubl.). Briefly, C57BL/6J x CBA/J F 1 female mice were induced
to superovulate by injection of pregnant mares' serum gonadotropin followed by hCG 48-50 hr later. Ovulated oocytes were
activated 19-21 hr after hCG injection. Mature oocytes were
activated in embryo culture medium (TE) (Spindle 1990) containing 6% ethanol (vol/vol) and 50 ~tM EDTA for 4.5 min,
washed through FM-I, and transferred to TE containing 50 lzM
EDTA and 0.5 ~g/ml of cytochalasin D for 5 hr to block extrusion of the second polar body. The parthenogenetic embryos
were then washed through FM-I, and intact embryos were transferred in groups of 20 to individual drops of TE containing 50 fzM
EDTA and cultured at 37°C. The efficiency of activation, determined from two-cell parthenogenetic embryos at 24 hr, was
65-85%. Control zygotic embryos were produced by mating F 1
females with F~ males. Parthenogenetic outgrowths were cultured in outgrowth medium {Spindle 1990) for 3-7 days after
hatching of blastocysts.

Materials
Amplitaq DNA polymerase was purchased from Perk(n-Elmer
Cetus. Restriction enzymes and T4 polynucleotide kinase were
purchased from New England BioLabs and Bethesda Research
Laboratories (BRL). Radioisotopes were obtained from New England Nuclear. Moloney murine leukemia virus (MMLV) reverse transcriptase and Superscript MMLV reverse transcriptase
were obtained from BRL. Ant(sense, sense, and PCR oligonucleotides were obtained from the University of California at San
Francisco (UCSF) Biomolecular Resource Center or synthesized
in our laboratory on an Applied Biosystems PCR-Mate oligosynthesizer. Biosynthetic insulin and IGF-II were gifts of Eli
Lilly, and recombinant human IGF-II and IGF-I were purchased
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Embryo culture
For each analysis, 30-40 embryos were cultured from the twocell stage in CZB medium (Chatot et al. 1989) or 20 embryos/
20-~1 drop in TE (Spindle et al. 1990) under paraffin oil (Aldrich)
to the blastocyst stage. All experiments were performed at least
twice.

Biosynthetic labeling of embryos
Two-cell embryos (400-600) were incubated for 48 hr in TE
alone or in TE with 100 nM IGF-II, insulin (Eli Lilly), or IGF-I
(Bachem). For the last 4 hr, embryos were incubated with or
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without fresh growth factors and 1 m C i / m l of [3SS]methionine
(3000 Ci/mmole} as described previously (Brenner et al. 1989).
At the end of the labeling period, embryos were washed through
8 drops of TE and duplicate samples from triplicate drops precipitated onto glass filters by using 6% TCA (wt/vol), and dried
and assayed by liquid scintillation spectrometry. In some experiments, the washed embryos were solubilized in loading buffer
and applied directly and proteins were separated by 12% SDS-polyacrylamide gel electrophoresis and analyzed by fluorography.

RNA preparation
A microadaptation (Rappolee et al. 1988a, 1989) of the guanidine isothiocyanate (GuSCN)-CsC1 gradient ultracentrifugation technique was used to prepare total RNA from 100--200
embryos {Chirgwin et al. 1979). Embryos flushed from the genital tract at specific stages or cultured to specific stages were
washed though 6 drops of FM-I, solubilized in 100 ~1 of GuSCN
containing 20 ~g of Escherichia coli rRNA (Boehringer Mannhelm), and layered over 100 ~1 of 5.7 M CsC1 and centrifuged for
2 hr at 80,000 rpm in a TL-100A rotor in a Beckman TL-100
benchtop ultracentrifuge. Yields of RNA were based on carrier
amount and ranged from 35% to 80%. RNA used for positive
controls was isolated from macrophages or retinoic acid-treated
F9 cells, as described previously (Rappolee et al. 1988b; Brenner
et al. 1989; Hahnel et al. 1990). The concentration of RNA was
determined by measurement of absorbance at 260 nm.

RT-PCR
RT-PCR was performed essentially as described previously
(Rappolee et al. 1988a,b, 1989). Briefly, RNA was reverse transcribed with MMLV reverse transcriptase or Superscript MMLV
reverse transcriptase primed with 0.2 p~g of random hexanucleotides (Pharmacia) or 0.5 ~g of 12- to 18-mer oligo(dT) (Collaborative Research) with 100 units of enzyme in a 20-~1 mixture.
In early studies on IGF-II expression, reaction mixtures were
heat denatured and flash cooled; 50 units of additional buffered
Superscript MMLV was added, and the RT mixture was reincubated. The proportion of the RT mixture that was equivalent to
10 embryos was added to sequence-specific primed PCR reaction mixture in a buffer containing 10 mM Tris-HC1 (pH 8.3),
600 t~M each dNTP, 5 ~M trimethyl ammonium chloride
(Sigma), and 4.0 mM MgC12 in a 50-~1 reaction mixture (Rappolee et al. 1988a). The mixture was overlaid with 100 ~1 of
mineral oil and amplified for 60 cycles on a Perkin-Elmer Cetus
Thermocycler programmable heating block. The PCR fragments were separated on a 4% agarose (3% G T G / I % Seakem,
FMC Corp.) gel and visualized by ethidium bromide staining.
Gels were photographed with a Polaroid MP-4, and negative
images were reversed. Fragments were verified by size, restriction enzyme mapping, sequence analysis, and Southern blot
analysis as described previously (Brenner et al. 1989; Telford et
al. 1990). For restriction enzyme analysis, the fragments were
precipitated with ammonium acetate directly from the PCR
mixture, washed twice with 70% ethanol, and digested according to the restriction enzyme manufacturer's instructions.
For quantification of mRNA, PCR was performed with endlabeled oligonucleotides: 5 ~l of the 3' and 5' primers at 50
pmole/~l was mixed with 5 ~1 of T4 polynucleotide kinase
{10,000 U/ml; New England BioLabs) and 250 txCi of [y-32p]ATP
and incubated overnight at ambient temperature (Chelly et al.
1988). Unincorporated radionucleotides were removed, and the
labeled primers were used in 24 reactions. Fourfold dilutions
were mixed and amplified as described for 40 cycles (Fig. 7a).

Products were separated by 6% polyacrylamide gel electrophoresis and autoradiographed, the bands were excised, and radioactivity was determined by liquid scintillation spectrometry.

Immunofluorescence and nuclear staining
For immunocytochemistry, blastocysts were either fixed in solution without centrifugation or centrifuged onto poly-t-lysinecoated coverslips in a Shandon cytocentrifuge at 900 rpm for 30
min and fixed in 2% paraformaldehyde (pH 7.2). The blastocysts
were stained with rabbit polyclonal anti-rat IGF-II antibody (diluted at 1 : 200) with or without 0.5 ~g of rat IGF-II to absorb the
anti-IGF-II antibody. The primary antibody was followed by biotinylated anti-rabbit IgG and then with streptavidin-Texas
Red as described previously (Rappolee et al. 1988a). Embryos
fixed and stained in solution were viewed in rectangular microcapillary tubes (Vitro Dynamics). Rhodamine-phalloidin was
used to visualize actin as a control protein. All photography was
performed with a Zeiss Photomicroscope III and water immersion 25 x or 63 x phase Plan-Neofluor lenses, and Tri-X film was
exposed and developed under similar lighting conditions.
To determine the response of embryos, IGF-I (Amgen), IGF-II
(Eli Lilly), and [Leu2Z]IGF-II were serially diluted in 100-~1 volumes and added at appropriate concentrations with 20 two-cell
embryos in 20-~1 droplets under oil and cultured for 3 days;
blastocysts were then fixed onto glass coverslips and stained.
For staining of nuclei, embryos were fixed in solution by 3 : 1
(vol/vol) ethanol/glacial acetic acid, dried onto coverslips, and
incubated in 1 ~g/ml of Hoechst 33258 in water for 5 rain and
destained overnight (Handyside and Hunter 1984). Nuclei were
photographed as described above.

Antisense oligonucleotide experiments
To determine the incorporation of oligonucleotides into embryos, the sense and antisense oligonucleotides were end-labeled as described above for RT-PCR. Compacted eight-cell embryos were incubated with 30 p~Mlabeled oligonucleotides for 24
hr in 20-~1 drops of TE. Embryos were then washed six times
and incubated in TE medium without labeled oligonucleotides
for 6 hr, washed through 6 more drops of unlabeled medium,
fixed onto microscope slides, coated with photographic emulsion, and exposed and developed. Control embryos were incubated with 30 ~M unlabeled oligonucleotides for 24 hr, washed
through medium with labeled oligonucleotides for 1 min, and
treated as described above. In some experiments, blastocysts
were washed and incorporation of labeled oligonucleotides per
20 embryos was determined by liquid scintillation spectrometry. Incorporation per blastocyst (counts per minute) was calculated by dividing total counts per minute by the number of
blastocysts. The number of oligonucleotide molecules per blastocyst was then determined from the specific activity of the
labeled oligonucleotides (Holt et al. 1988).
For determination of the effects of oligonucleotides on
growth, two-cell embryos were cultured in 30 ~M sense or antisense IGF-II oligonucleotides in 20-vd drops of TE for 72 hr
with or without 10 nM recombinant IGF-II. The percentage of
embryos reaching the blastocyst stage was determined by phase
microscopy at 24-hr intervals. The effects on endogenous IGF-II
were studied by centrifuging the embryos onto coverslips after
72 hr and then staining for immunofluorescence with anti-IGFII antibodies as described above. For determination of effects on
specific mRNAs from the cultured embryos, RNA was isolated
and IGF-II and GAPDH transcripts were assayed by RT-PCR
and quantified as described above. Effects on cell number were
determined by fixing embryos onto coverslips and counting nu-
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clei after Hoechst staining as described above. All experiments
were performed at least twice. All values are expressed as mean
+S.D. for three replicates.

Oligonucleotides
The designs of oligonucleotides used in this study showing sequence position by amino acid residue or nucleotide are given
below.

Initiation codon oligonucleotides IGF-II (mouse; amino acid
- 24) antisense, 5'-TGGGGATCCCAGTGGGGTAC-3'; IGF-II
(mouse; amino acid -24) sense, 5'-GTACCCCACTGGGATCCCCA-3'.
PCR primers IGF-II (mouse; amino acid 3) 5' primer, 5'-GGCCCCGGAGAGACTCTGTGC-3'; IGF-II (mouse; amino acid
87) 3' primer, 5'-GCCCACGGGGTATCTGGGGAA-3'; IGF-I
{rat; amino acid 1) 5' primer, 5'-GGACCAGAGACCCTTTGCGGGG-3'; IGF-I (rat; amino acid 70) 3' primer, 5'-GGCTGCTTTTGTAGGCTTCAGTGG-3'; insulin (mouse; nucleotide 1144) 5' primer, 5'-ATGCGCTTCCTGCCCCTGCTGGC-3'; insulin (mouse; nucleotide 1931) 3' primer, 5'-CTGGTAGAGGGAGCAGATGCTGGT-3'; IGF-II receptor (rat; nucleotide 5048)5' primer, 5'-TGTACACTCTTCTTCTCCTGGCA-3'; IGF-II receptor (rat; nucleotide 5233) 3' primer,
5'-AGAGATGTTGATGTAGAAGACAGG-3'; IGF-I receptor
(human; nucleotide 3769) 5' primer, 5'-ACTGACCTCATGCGCATGTGCTGG-3'; IGF-I receptor (human; nucleotide 4113) 3'
primer, 5'-CTCGTTCTTGCGGCCCCCGTTCAT-3'; insulin
receptor (human; nucleotide 3934) 5' primer, 5'-ACTGACCTCATGCGCATGTGCTGG-3'; insulin receptor (human; nucleotide 4252) 3' primer, 5'-GCCCGTTTTTCTTGCCTCCGTTCAT-3'; GAPDH (rat/human; nucleotide 838) 5' primer,
5'-TGACATCAAGAAGGTGAAG-3'; GAPDH (rat/human;
nucleotide 1087) 3' primer, 5'-TCCTTGGAGGCCATGTAGGCC-3'. The sources for the sequences and sequence positions
used are as follows: mouse IGF-II (Stempien et al. 1986); rat
IGF-I (Bell et al. 1986); mouse insulin (Wentworth et al. 1986);
rat IGF-II receptor (unpublished sequence from D.O. Morgan,
UCSF); human IGF-I receptor and insulin receptor (Ebina et al.
1985; Ullrich et al. 1985, 1986). Actin oligonucleotides have
been published previously (Rappolee et al. 1988a).
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